Navigation Links
OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Date:4/9/2009

BOTHELL, WA, and VANCOUVER, April 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), announced today that it has been named the 2009 Life Sciences Company of the Year by LifeSciences British Columbia. This annual award is presented by LifeSciences British Columbia to recognize a local organization that has made outstanding contributions to the development of British Columbia's life sciences industry. This award recognizes a company for execution of business strategies, scientific excellence, leadership and vision and market position/opportunity. The organization also uses this award to increase public awareness and understanding of life sciences in the province.

"We are very pleased to be recognized for this award, especially in light of what was a particularly challenging economic environment in 2008," said Scott Cormack, President and CEO of OncoGenex. "For OncoGenex, 2008 was a tremendously active year as we took measures to prepare for the final stages of clinical development of our lead product candidate, OGX-011, for the treatment of cancer. We released Phase 2 clinical data showing a survival benefit in patients treated with OGX-011 and are working closely with the FDA to develop Phase 3 study designs and protocols defining a registration path for product approval. We also took measures to extend our cash runway, and we have been advancing discussions with potential development partners."

"There is no greater honour than to be recognized by one's peers," added Cormack. "I'd like to thank all the employees at OncoGenex, as this award was earned by each and every one of them through their dedication, hard work and loyalty."

About LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, biopro
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 In recent years, the biopharmaceutical ... Big Data that can generate valuable insights. Despite this, ... Big Data have caused the biopharmaceutical sector to embrace ... According to a recent study by benchmarking ... a Big Data team or function in place; however, ...
(Date:5/29/2015)... 2015 Market Publishers Ltd and ... a partnership agreement for quality market research promotion ... and sell research reports worked out by Chem-Report. ... commented upon the agreement: “Chem-Report is a Chinese ... and chemical markets on global and country levels. ...
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ... new report "Cytogenetics - Technologies, Markets and ... report deals with cytogenetics in a broader sense ... the chromosome structure and identify abnormalities related to ... is also referred to as molecular cytogenetics. The ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... ) has announced the addition of Jain ... Drugs, Markets and Companies"  to their offering.  ... ,Alzheimer,s disease remains a challenge in management. ... condition in the seven major markets of ...
Breaking Biology Technology:New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... June 15 BioMed Realty Trust, Inc. (NYSE: BMR ) today ... $0.15 per share of common stock, representing a 7.1% increase over the ... equivalent to an annualized dividend of $0.60 per common share. , ... BioMed also announced that its board of directors has ...
... ARBOR, Mich. , June 15 Two Ann Arbor ... in the region.  NanoBio Corporation and Grand River were approved today for MEGA ... Michigan . , , , ... reflect the broad array of technical acumen in our region,s continuously growing business ...
... , June 15 New data from a retrospective cohort ... (PD) developed gastrointestinal disorders (GID) that can have a substantial adverse effect ... at the 14th International Congress of Parkinson,s Disease and Movement Disorders in ... , , ...
Cached Biology Technology:BioMed Realty Trust Declares Second Quarter 2010 Common Stock and Preferred Stock Dividends 2BioMed Realty Trust Declares Second Quarter 2010 Common Stock and Preferred Stock Dividends 3NanoBio and Grand River Expand in Ann Arbor with $2.5 Million in Capital Investment Commitments 2NanoBio and Grand River Expand in Ann Arbor with $2.5 Million in Capital Investment Commitments 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... the Bronx Zoo-based Wildlife Conservation Society (WCS) warn that ... Asia and beyond must focus on better management practices ... working with Mongolian agencies on the ground in Mongolia's ... recently contracted the virus. , "We're working with our ...
... modest suppression of growth hormone and related compounds beginning ... of several types of cancer, researchers from Wake Forest ... at ENDO 2005, the annual meeting of the Endocrine ... and insulin-like growth factor (IGF-1) also may decrease cancer ...
... researchers have discovered an inherited structural mechanism that ... some patients. The mechanism decreases a protein and ... drugs differently. Thiopurine therapies are used to treat ... transplants. The Mayo researchers say their finding advances ...
Cached Biology News:WCS says avian flu prevention should focus on farms, markets 2Suppressing growth hormone in early adulthood may prevent cancer 2Genomics researchers discover protein deficit that causes drug toxicity 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... kit #27295 has improved stability and convenience from ... not only has overcome this problem but also ... have changed the formulation of HRP conjugated antibody ... By this change, the stability of the conjugate ...
Biology Products: